2017+BC指南:无法治愈性癌症或晚期疾病患者的姑息治疗-2.疼痛和症状管理

2017-02-22 不列颠哥伦比亚省临床实践指南中心 不列颠哥伦比亚省临床实践指南中心官网

2017年3月,不列颠哥伦比亚省临床实践指南中心(BC)发布了无法治愈性癌症或晚期疾病患者的姑息治疗指南,该指南主要包括3大部分内容,主要为≥19岁无法治愈的癌症和终末期疾病患者提供姑息治疗评估和管理策略。

中文标题:

2017+BC指南:无法治愈性癌症或晚期疾病患者的姑息治疗-2.疼痛和症状管理

英文标题:

Palliative Care for the Patient with Incurable Cancer or Advanced Disease Part 2: Pain and Symptom Management

发布日期:

2017-02-22

简要介绍:

2017年3月,不列颠哥伦比亚省临床实践指南中心(BC)发布了无法治愈性癌症或晚期疾病患者的姑息治疗指南,该指南主要包括3大部分内容,主要为≥19岁无法治愈的癌症和终末期疾病患者提供姑息治疗评估和管理策略。

 

拓展指南:癌症相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2017+BC指南:无法治愈性癌症或晚期疾病患者的姑息治疗-2.疼痛和症状管理)] GetToolGuiderByIdResponse(projectId=1, id=bf35a1c001ae5365, title=2017+BC指南:无法治愈性癌症或晚期疾病患者的姑息治疗-2.疼痛和症状管理, enTitle=Palliative Care for the Patient with Incurable Cancer or Advanced Disease Part 2: Pain and Symptom Management, guiderFrom=不列颠哥伦比亚省临床实践指南中心官网, authorId=null, author=, summary=2017年3月,不列颠哥伦比亚省临床实践指南中心(BC)发布了无法治愈性癌症或晚期疾病患者的姑息治疗指南,该指南主要包括3大部分内容,主要为≥19岁无法治愈的癌症和终末期疾病患者提供姑息治疗评估和管理策略。 , cover=, journalId=null, articlesId=null, associationId=1229, associationName=不列颠哥伦比亚省临床实践指南中心, associationIntro=, copyright=0, guiderPublishedTime=Wed Feb 22 00:00:00 CST 2017, originalUrl=, linkOutUrl=, content=<P>2017年3月,不列颠哥伦比亚省临床实践指南中心(BC)发布了无法治愈性癌症或晚期疾病患者的姑息治疗指南,该指南主要包括3大部分内容,主要为≥19岁无法治愈的癌症和终末期疾病患者提供姑息治疗评估和管理策略。 </P> <P> </P>拓展指南:<strong>与<font color=red>癌症</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=f69411c001ae5256" title="2017+BC指南:无法治愈性癌症或晚期疾病患者的姑息治疗-1.护理方法" target=_blank>2017+BC指南:无法治愈性癌症或晚期疾病患者的姑息治疗-1.护理方法</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=2f8fc1c001a66036" title="2017 意见书:成人癌症患者铁缺乏的管理" target=_blank>2017 意见书:成人癌症患者铁缺乏的管理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=9cfb91c001a64e54" title="NCCN临床实践指南:癌症相关性静脉血栓栓塞性疾病(2017.V1)" target=_blank>NCCN临床实践指南:癌症相关性静脉血栓栓塞性疾病(2017.V1)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=d04561c001a62435" title="NCCN临床实践指南:癌症和化疗诱导的贫血(2018.V1)" target=_blank>NCCN临床实践指南:癌症和化疗诱导的贫血(2018.V1)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=043751c001a6121b" title="辅助性二膦酸盐和其他骨修复剂在乳腺癌中的应用:安大略省癌症护理协会和美国临床肿瘤学会临床实践指南" target=_blank>辅助性二膦酸盐和其他骨修复剂在乳腺癌中的应用:安大略省癌症护理协会和美国临床肿瘤学会临床实践指南</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E7%99%8C%E7%97%87" target=_blank>有关癌症更多指南</a></ul>, tagList=[TagDto(tagId=55355, tagName=无法治愈性癌症), TagDto(tagId=55356, tagName=晚期疾病)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=29, categoryName=麻醉疼痛科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=4, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3609, appHits=107, showAppHits=0, pcHits=2773, showPcHits=1087, likes=170, shares=9, comments=3, approvalStatus=1, publishedTime=Thu Jul 27 22:02:26 CST 2017, publishedTimeString=2017-02-22, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Thu Jul 27 22:02:26 CST 2017, updatedBy=null, updatedName=null, updatedTime=Wed Jan 03 18:21:50 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2017+BC指南:无法治愈性癌症或晚期疾病患者的姑息治疗-2.疼痛和症状管理)])
2017+BC指南:无法治愈性癌症或晚期疾病患者的姑息治疗-2.疼痛和症状管理
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=955741, encodeId=d4d5955e4139, content=有帮助, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2d42175818, createdName=shenaomei_81242377, createdTime=Sat Apr 10 19:33:19 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955740, encodeId=8b8d955e4083, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2d42175818, createdName=shenaomei_81242377, createdTime=Sat Apr 10 19:31:48 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896839, encodeId=2d2889683978, content=特别好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3405327796, createdName=148c1ad7m20暂无昵称, createdTime=Wed Nov 04 12:01:52 CST 2020, time=2020-11-04, status=1, ipAttribution=)]
    2021-04-10 shenaomei_81242377

    有帮助

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=955741, encodeId=d4d5955e4139, content=有帮助, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2d42175818, createdName=shenaomei_81242377, createdTime=Sat Apr 10 19:33:19 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955740, encodeId=8b8d955e4083, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2d42175818, createdName=shenaomei_81242377, createdTime=Sat Apr 10 19:31:48 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896839, encodeId=2d2889683978, content=特别好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3405327796, createdName=148c1ad7m20暂无昵称, createdTime=Wed Nov 04 12:01:52 CST 2020, time=2020-11-04, status=1, ipAttribution=)]
    2021-04-10 shenaomei_81242377

    👍

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=955741, encodeId=d4d5955e4139, content=有帮助, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2d42175818, createdName=shenaomei_81242377, createdTime=Sat Apr 10 19:33:19 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955740, encodeId=8b8d955e4083, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2d42175818, createdName=shenaomei_81242377, createdTime=Sat Apr 10 19:31:48 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896839, encodeId=2d2889683978, content=特别好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3405327796, createdName=148c1ad7m20暂无昵称, createdTime=Wed Nov 04 12:01:52 CST 2020, time=2020-11-04, status=1, ipAttribution=)]
    2020-11-04 148c1ad7m20暂无昵称

    特别好

    0